Results 101 to 110 of about 5,389 (186)

Efectos oculares secundarios al tratamiento quimioterápico y radioterápico en las patologías neoplásicas [PDF]

, 2019
1. Introducción . El cáncer tuvo en el 2018 una incidencia mundial de 18.078.957, siendo una autén tica lacra p ara la sal ud mundial, entre otras cosas, por su difícil manejo.
Parrilla Álvarez, Magdalena
core  

Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report

Cancer Reports
Background Erdheim–Chester disease (ECD) is a rare form of non‐Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen‐activated protein kinase/extracellular signal‐regulated kinase (MAPK/ERK ...
Yuto Hibino, Rika Sakai, Hiroyuki Takahashi, Takaaki Takeda, Natsuki Hirose, Mayumi Tokunaga, Kota Washimi, Tomoyuki Yokose, Rika Kasajima, Yukihiko Hiroshima, Yohei Miyagi, Hideaki Nakajima   +11 more
doaj   +1 more source

Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome

JAAD Case Reports, 2021
Peter A. Young, MPAS, BS, Lia C. Keller, MD, Gordon H. Bae, MD   +2 more
doaj   +1 more source

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor [PDF]

, 2017
et al,, Tan, Benjamin R
core   +2 more sources

Statistical classification of treatment responses in mouse clinical trials for stratified medicine in oncology drug discovery

Scientific Reports
Translational oncology research strives to explore a new aspect: identifying subgroups that exhibit treatment response even during pre-clinical phases. In this study, we focus on PDX models and their implementation in mouse clinical trials (MCT).
Hélène Savel, Florence Meyer-Losic, Cécile Proust-Lima, Laura Richert   +3 more
doaj   +1 more source

Resistance to MAPK Pathway Inhibition in BRAF-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors

Organoids
The current treatment for refractory BRAF-V600E mutant metastatic colorectal cancer (mCRC) involves combined inhibition of BRAF and the epidermal growth factor receptor (EGFR).
Layla El Bouazzaoui, Daniëlle A. E. Raats, André Verheem, Inne H. M. Borel Rinkes, Hugo J. G. Snippert, Madelon M. Maurice, Onno Kranenburg   +6 more
doaj   +1 more source

Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification

Frontiers in Pharmacology
BackgroundColorectal cancer (CRC) is the leading cancer among Saudis, and mutations in BRAF, KRAS, and NRAS genes are therapeutically significant due to their association with pathways critical for cell cycle regulation.
Thamer Abdulhamid Aljuhani, Thamer Abdulhamid Aljuhani, Noor Ahmad Shaik, Noor Ahmad Shaik, Rahaf Talal Alqawas, Rana Y. Bokhary, Mahmood Al-Mutadares, Hadiah Bassam Al Mahdi, Nuha Al-Rayes, Ashraf AbdulRahman El-Harouni, Ramu Elango, Ramu Elango, Babajan Banaganapalli, Babajan Banaganapalli, Zuhier Ahmad Awan   +14 more
doaj   +1 more source

Encorafenib [PDF]

, 2020
openaire   +1 more source

Exceptional case of tumor lysis syndrome following Encorafénib-Binimétinib therapy for metastatic melanoma

EJC Skin Cancer
We report a case of tumor lysis syndrome (TLS) occurring 48 h after initiation of targeted therapy with Encorafénib and Binimétinib in a patient with an extensive metastatic melanoma harboring a BRAF V600E mutation.
Adielle Abecassis, Laura Perray, Rafaele Molinier, Safa Idoudi, Helene Kemp, Céleste Lebbé, Laetitia Vercellino, Emilien Ezine, Marie Fournier   +8 more
doaj   +1 more source

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer [PDF]

, 2019
BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy.
Anderson, L, Arkenau, H-T, Braun, M, Calvo Ferrandiz, A, Christy-Bittel, J, Ciardiello, F, Dekervel, J, Desai, J, Elez, E, Garcia-Alfonso, P, Gollerkeri, A, Grothey, A, Guo, C, Guren, TK, Hong, YS, Keir, C, Kim, T-W, Kopetz, S, Krishnan, A, Lonardi, S, Loupakis, F, Maharry, K, Morris, V, Orlov, S, Pfeiffer, P, Pickard, M, Sandor, V, Schellens, JHM, Steeghs, N, Tabernero, J, Tarpgaard, LS, Van Cutsem, E, Wasan, H, Yaeger, R, Yoshino, T   +34 more
core